WebDisclosure WebDisclosure
Basculer en Français
11376 Companies
252795 Keywords
182325 Articles
138522 Press releases
Headlines Articles Press releases Hansoh Pharma Remove
  1. Home
  2. Companies
  3. Hansoh Pharma
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 10/02/2026 at 06:10, 1 month 17 days ago

    Hansoh Pharma's Olatorepatide Shows Promise in Weight Loss Study

    Weight Loss Phase III Study Olatorepatide GLP-1/GIP Agonist Hansoh Pharma
  • BRIEF

    published on 10/02/2026 at 06:10, 1 month 17 days ago

    L'olatorépatide de Hansoh Pharma se révèle prometteur dans une étude sur la perte de poids

    Perte De Poids Étude De Phase III Olatorepatide Hansoh Pharma Agoniste Du GLP-1/GIP
  • PRESS RELEASE

    published on 10/02/2026 at 06:05, 1 month 17 days ago

    19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD

    Phase III data of Hansoh Pharma's Olatorepatide, a dual-biased GLP-1/GIP agonist, showing 19.3% weight loss efficacy at Week 48 presented at EASD. Study demonstrates significant weight loss benefits and metabolic improvements
    Weight Loss Olatorepatide GLP-1/GIP Agonist Hansoh Pharma EASD
    Logo of Hansoh Pharma
Accesswire
  • Published on 11/19/2026 at 10:00, 50 minutes ago

    Temas Signs RCL Validation Services Contract with Québec Mineral Company Near La Blache and Proposed Baie-Comeau Demonstration Plant Site; Appoints Anthony Travers to Board

  • Published on 11/19/2026 at 04:25, 6 hours 25 minutes ago

    Predictiv AI Announces Appointment of Interim Chief Executive Officer

  • Published on 11/18/2026 at 23:30, 11 hours 20 minutes ago

    Jericho Energy Ventures Provides Update on Oil and Gas Joint Venture Credit Facility

  • Published on 11/18/2026 at 23:30, 11 hours 20 minutes ago

    Presentation to Swiss Mining Institute Conference

  • Published on 11/18/2026 at 21:15, 13 hours 35 minutes ago

    Sparta Capital Ltd. Announces Resumption of Trading

View all ACCESSWIRE
EQS Group
  • Published on 11/19/2026 at 10:36, 14 minutes ago

    New exploration licence expands Vulcan’s low-cost growth potential

  • Published on 11/19/2026 at 10:32, 18 minutes ago

    Holding(s) in Company

  • Published on 11/19/2026 at 10:30, 20 minutes ago

    DAR GLOBAL AND THE TRUMP ORGANIZATION MARK SUCCESSFUL LAUNCH OF $700M QATAR DESTINATION TO INTERNATIONAL INVESTORS

  • Published on 11/19/2026 at 10:30, 20 minutes ago

    GBC AG returns as a partner of the Deutsches Eigenkapitalforum 2026

  • Published on 11/19/2026 at 10:27, 23 minutes ago

    Sempora study confirms: Shop Apotheke is consumers’ first choice and leads in perceived healthcare expertise.

View all EQS
Les Echos
  • Published on 11/19/2026 at 08:30, 2 hours 20 minutes ago

    Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing

  • Published on 11/19/2026 at 08:30, 2 hours 20 minutes ago

    Souveraineté des données : Cegedim ouvre EB6, un datacenter nouvelle génération pour l'IA et la haute densité

  • Published on 11/19/2026 at 08:00, 2 hours 50 minutes ago

    EXOR TO RAISE ITS STAKE IN BIOMÉRIEUX

  • Published on 11/19/2026 at 08:00, 2 hours 50 minutes ago

    EXOR VA RENFORCER SA PARTICIPATION DANS BIOMÉRIEUX

  • Published on 11/19/2026 at 07:30, 3 hours 20 minutes ago

    Gimv investeert in SpiraTec, specialist in automatisering en digitale transformatie in de procesindustrie

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy